The German health authorities reported early this Sunday (01.09.2022) that 36,552 new SARS-CoV-2 infections were registered in the last 24 hours, which contrasts with the 12,515 detected a week ago, although the data from then were not considered completely realistic due to the lag of the Christmas break, with fewer exams and gaps in the delivery of results.
In addition, the cumulative incidence over seven days amounted to 362.7 infections per 100,000 inhabitants, compared to 335.9 on Saturday and 222.7 seven days ago, according to data from the Robert Koch Institute of Virology (RKI), an entity in charge of monitoring the pandemic in the European country. Likewise, the death of 77 people due to causes associated with covid-19 was reported, bringing the total number of deaths to 113,977.
Since the beginning of the health crisis, Germany has officially added 7,510,436 infections, although it is assumed that the real figure is notoriously higher, as not all cases are registered. The contagions in Germany have experienced a continuous rise since the end of the year and have again reached the levels of mid-December, when the country was immersed in the fourth wave, something that experts attribute to the expansion of the omicron variant.
New high-risk territories
The rate of hospitalizations due to covid reached 3.5 per 100,000 inhabitants, also on the rise compared to previous days, while 15.1 percent of beds in intensive care units are occupied by patients with the disease caused. by the coronavirus. The number of reproduction of the virus, meanwhile, reached 1.34, which means that 100 carriers of SARS-CoV-2 infect another 134 people.
On the other hand, this morning the classification of almost 40 new countries as high-risk territories came into force, with which the list of the German Foreign Ministry already includes a total of more than 100 states around the world. Among the new additions to the list are European countries such as Estonia, France, Luxembourg, the Netherlands and Sweden, and several from America, such as Argentina, Bolivia, Panama and Uruguay.
The classification implies that those who arrive in Germany from these territories must keep 10 days of quarantine – which can be shortened to five with a negative test – if they are not vaccinated with the full schedule or have already overcome an infection.
The vaccines that promise to defeat the coronavirus
Sputnik V, Instituto Gamaleya
The “Russian vaccine” aroused initial mistrust, but it has established itself as an option for a score of countries, including Argentina, Bolivia and Venezuela. The doubts arose due to its rapid approval, in August 2020, without having finished the tests. However, subsequent studies give a high efficacy to this preparation, which uses adenoviral vectors to elicit immunity.
–
–
The vaccines that promise to defeat the coronavirus
BNT162b2, BioNTech/Pfizer
The vaccine from the German firm BioNTech uses a previously unpublished technology: lipid-covered mRNA. Simply explained, the vaccine “mimics” the form of SARS-CoV-2, eliciting the body’s response. In trials it showed high efficacy, which has been replicated in real conditions. Pfizer is serving in the alliance as a manufacturing partner. It is used in about twenty countries.
–
–
The vaccines that promise to defeat the coronavirus
mRNA-1273, Modern
The vaccine developed by the National Institute of Allergies and Infectious Diseases, the Advanced Biomedical Research and Development Authority (BARDA), and the Moderna firm uses technology similar to BioNTech’s. In trials it demonstrated an efficacy close to 95 percent. Unlike BioNTech, this formula can be stored at -20 degrees. It is used in the US and the European Union.
–
–
The vaccines that promise to defeat the coronavirus
AZD1222, Oxford-AstraZeneca
This vaccine developed by British and Swedish experts uses a modified chimpanzee adenovirus as a vector. The trials took place in the UK, Brazil, South Africa, Japan and India, and were interrupted a couple of times by suspicious deaths. However, its safety and efficacy ranging from 60 to 90 percent have been confirmed. It is used in Brazil, the EU and the UK.
–
–
The vaccines that promise to defeat the coronavirus
Ad5-nCoV, Cansino Biologics
The vaccine from this Chinese firm uses the common cold adenovirus to introduce an inactivated SARS-CoV-2 protein into the human body, eliciting an immune response. It has been used in China to inoculate People’s Army soldiers, and trials were carried out in Russia, Pakistan, Mexico, Chile, and Argentina. It is currently used in Mexico, Malaysia, and Indonesia. Use only one dose.
–
–
The vaccines that promise to defeat the coronavirus
CoronaVac, Sinovac Biotech
Like many vaccines that use inactivated viruses, this formula uses SARS-CoV-2 particles obtained in cultures and inactivated before being injected into the body. The presence of these viruses triggers the immune reaction and prevents the disease from developing. Tested in Brazil, Indonesia, Chile and Turkey, it shows an effectiveness of over 60 percent.
–
–
The vaccines that promise to defeat the coronavirus
BBV152, Bharat Biotech
Also virus-inactivated, this vaccine developed by Bharat and the Indian Council for Medical Research is known as Covaxin, and has shown 81 percent efficacy in clinical trials. At the time, it sparked controversy for having been inoculated in medical workers when the formula was still in phase I clinical trials. India is now seeking approval in other markets.
–
–
The vaccines that promise to defeat the coronavirus
BBIBP-CorV, Sinopharm
With trials in Argentina, Peru, the United Arab Emirates and other states, this Chinese inactivated virus vaccine has already been approved in Middle Eastern countries. According to studies, it would be 86 percent effective. Sinopharm is in the eye of controversy in Peru for having sent “courtesy vaccines” for politicians and for having donated thousands of dollars to the government.
–
–
The vaccines that promise to defeat the coronavirus
Ad26.COV2.S, Johnson & Johnson
Along with CanSino’s, it is the only single-dose vaccine to date. It is developed by the Belgian firm Janssen Pharmaceutica, a subsidiary of the American Johnson & Johnson. It can be stored in a normal refrigerator and has been shown to be more than 66 percent efficient. It uses a non-replicative viral vector derived from human adenovirus A26.
